Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cilostazol för förebyggande av återkommande stroke i Afrika (CLARITY-Africa)

10 november 2026 uppdaterad av: Bruce Ovbiagele, Northern California Institute of Research and Education

Global estimates suggest that sub-Saharan Africa (SSA) now has the highest incidence, prevalence, and worst survival outcomes of stroke. With an estimated 1.4 million stroke survivors, outcomes of stroke in SSA are abysmal with 1-month case fatality at 30% and 3-year mortality rate of 84%. Stroke survivors in Africa are at an inordinately high (and worsening) risk of adverse outcomes including recurrent stroke and cardiac events over the medium- to longterm. Given the paucity of resources in the region, testing of therapies, which are potentially highly clinically efficacious and cost-effective, while developing local stroke research capacity and contributing to the global secondary stroke prevention evidence base, is urgently needed. Cilostazol, a phosphodiesterase 3 inhibitor, has shown promising efficacy and safety mainly among an Asian population by cutting risk of major adverse cardiovascular events including stroke, in half, when added to aspirin or clopidogrel (8% vs. 4%, HR 0.52, 95% CI 0.35-0.77), with no increased risk in bleeding or serious adverse events. Cilostazol's potentially strong efficacy, presumed pleiotropic effects, and relatively low cost, make it a highly appealing agent for use in stroke-prone, low-resource settings. Therefore, the overall objective of the CiLostAzol for pReventIon of recurrent sTroke in Africa (CLARITY-AFRICA) study is to deploy a hybrid study design to demonstrate the efficacy and safety of cilostazol twice daily in reducing MACE over 24 months vs. placebo among 1100 recent stroke patients encountered at 12 hospitals in Ghana. Secondly, CLARITY-AFRICA also seeks to develop an implementation strategy for routine integration and policy adoption of cilostazol for post-stroke cardiovascular risk reduction in an under-resourced system. Given its compelling efficacy among a predominantly Asian population, the National Institute of Neurological Disorders and Stroke (NINDS) is poised to fund a US-based clinical trial to assess the longer-term efficacy and safety of cilostazol in a study titled CiLostAzol for pReventIon of recurrent sTroke (CLARITY). The investigators are also aware that European and Australian funding agencies are considering stroke trials of cilostazol. A concurrently executed CLARITYAfrica trial would allow recruitment of a historically underrepresented and high-risk group (Africans), test a therapy that if efficacious could be affordable for broader regional implementation, permit transcontinental mentorship/collaborations, and leverage NINDS impending investment. CLARITY-AFRICA will assess implementation outcomes such as adoption, acceptability, cost, pertinent to uptake of cilostazol in Ghana to inform policy. Regardless of its outcome, findings from CLARITYAFRICA will contribute meaningful information from the African perspective to inform the formulation of guidelines for global adoption of cilostazol into routine care for secondary CVD risk prevention by international bodies such as the World Health Organization. This application will focus on the first 2 aims of CLARITY-AFRICA to conduct the trial and assess secondary outcomes.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

1100

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

      • Kumasi, Ghana
        • Kwame Nkrumah University of Science & Technology
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

30 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Above the age of 30 years; male or female (sex is a biological variable of interest)
  2. Ischemic stroke or high-risk TIA (ABCD2 score >= 6) diagnosis no greater than six months before enrollment. Ischemic strokes including lacunar, large vessel atherosclerotic, embolic stroke of undetermined source subtypes are eligible (Ischemic stroke or TIA should be confirmed by either with a cranial CT or MRI within 10 days of symptom onset)
  3. Aspirin or clopidogrel monotherapy
  4. Subjects with stroke may present with two or more of the following additional conditions: age ≥65 years, documented diabetes mellitus or previous treatment with oral hypoglycemic or insulin; documented hypertension >140/90mmHg or previous treatment with anti-hypertensive medications; Mild to moderate renal dysfunction (eGFR 60-30ml/min/1.73m2); Prior myocardial infarction
  5. Legally competent to sign informed consent or have a LARs who is able to provide consent for them
  6. In the opinion of the treating physician, patient is medically stable, capable of participating in a randomized trial, and willing and able to attend follow-up.
  7. Able to do labs at all study intervals (7 visits total)

Exclusion Criteria:

  1. Unable to provide a valid informed consent
  2. Contraindications to cilostazol (namely (i) hypersensitivity, (ii) active pathologic bleeding, e.g. bleeding peptic ulcer, intracranial bleeding due to reversible platelet aggregation, (iii) congestive cardiac failure.)
  3. Hemorrhagic stroke survivor within the last 2 years
  4. Use of an anticoagulant medication or indication for use of an anticoagulant (e.g. atrial fibrillation)
  5. On dual antiplatelet therapy (patients are eligible after completion of a course of dual antiplatelet therapy)
  6. Modified Rankin Scale 5
  7. Thrombocytopenia (platelet count <1000,000)
  8. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
  9. Congestive heart failure, defined as NYHA Class III or above (marked limitation of physical activity)
  10. Nursing/pregnant mothers

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Cilostazol Experimental Arm

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

Patients allocated to the experimental arm will receive 100mg of cilostazol tablets taken twice daily. To mitigate side-effects in both treatment arms, all patients will begin one tablet daily and titrate to the full dose (one tablet twice daily) after 2 weeks. Participants will stay on the full dose of cilostazol for the remainder of the study.

Inget ingripande: Control Arm

Standard of post-stroke care

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Procent av deltagarna med stora biverkningar
Tidsram: 36 månader
36 månader

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Procent av deltagarna med större och mindre blödning
Tidsram: 24 månader
24 månader
Procent av deltagarna med återkommande stroke (ischemisk eller hemorragisk)
Tidsram: 24 månader
24 månader
Procent av deltagarna med hjärt- och kärldödsfall
Tidsram: 24 månader
24 månader
Procent av deltagarna med alla orsakar dödlighet
Tidsram: 24 månader
24 månader
Neuro-QoL (Quality of Life)
Tidsram: 24 months

12 monthly

Neuro-QoL uses T-scores, which are standardized scores:

Mean (average) = 50 Standard deviation = 10

Interpreting T-scores:

Scores 0.5 - 1.0 SD worse than the mean = mild symptoms/impairment Scores 1.0 - 2.0 SD worse than the mean = moderate symptoms/impairment Scores 2.0 SD or more worse than the mean = severe symptoms/impairment

For negative domains (e.g. anxiety, depression, fatigue):

Higher = Worse

We will compare mean Neuro-QoL scores between the two arms of the study at study completion as well as proportions with mild, moderate and severe impairment.

24 months
Exploratory outcomes Montreal Cognitive Assessment
Tidsram: 24 months

6 monthly. Comparison of Slopes of MOCA scores over 24 months. Range of scores on MOCA: 0 to 30.

MOCA screening tool is used to detect mild cognitive impairment and early signs of dementia. It evaluates several cognitive domains, including:

Memory Attention Language Visuospatial skills Executive function Orientation

A score of 26 or above is considered normal. Scores below 26 may suggest cognitive impairment, depending on education level and clinical context.

24 months
Quality of Life (EQ-5D Questionnaire)
Tidsram: 24 months

The EQ-5D is a health-related quality of life questionnaire with two parts:

Descriptive system: Assesses 5 dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on 3 or 5 levels (from no problems to extreme problems).

Visual Analog Scale (VAS): Rates overall health from 0 (worst) to 100 (best).

Scoring:

The 5-digit health state is converted into a summary index score (range: <0 to 1), with 1 = full health.

The VAS reflects the person's self-rated health.

We will compare scores between the two arms at study completion.

24 months
Modified Rankin Score
Tidsram: 24 months

The Modified Rankin Scale (mRS) measures the degree of disability or dependence in daily activities after a stroke or other neurological injury.

Scoring:

0 - No symptoms

  1. - No significant disability; able to carry out all usual activities
  2. - Slight disability; unable to do all previous activities but able to look after own affairs
  3. - Moderate disability; needs some help but can walk unassisted
  4. - Moderately severe disability; unable to walk or attend to bodily needs without help
  5. - Severe disability; bedridden, incontinent, requires constant care
  6. - Dead
24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 januari 2027

Primärt slutförande (Beräknad)

31 juli 2029

Avslutad studie (Beräknad)

31 augusti 2029

Studieregistreringsdatum

Först inskickad

17 mars 2025

Först inskickad som uppfyllde QC-kriterierna

2 april 2025

Första postat (Faktisk)

9 april 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant level data will be aggregated and maintained as de-identified to protect PHI

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera